GNI Group 2160.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 2160.T. It has been listed since 31 August 2007. In the fiscal year to 31 December 2025, it reported revenue of ¥26.84bn and a net loss of ¥4.41bn. At that date it held total assets of ¥83.79bn and shareholders' equity of ¥50.15bn.

GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Ying LuoExecutive President, Chief Executive Officer, Representative Executive Officer, Chairman of Subsidiaries, Director, since 2009
• Mr. Tomoya KitagawaChief Financial Officer, Executive Officer, Director, since 2023
• Ms. Tracy MuExecutive Officer, Director of Finance and Accounting, Manager of President's Office
• Mr. Kazuki SekitaniChief Operating Officer, Executive Officer, Director, since 2023
• Mr. Kazuhiro KawachiExecutive Officer, Chief Business Development Officer
• Mr. Thomas EastlingDirector, since 2013
• Mr. Hei ChoIndependent Director
• Ms. Kanako KikuchiIndependent Director
• Mr. Ryosuke MatsuiIndependent Director
• Mr. Hideaki SashiwaIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.